In a study reported in the Journal of Clinical Oncology, Alan Pollack, MD, PhD, of University of Miami Miller School of Medicine, and colleagues compared escalated radiation dose using hypofractionated vs conventional fractionation intensity-modulated radiation therapy in men with favorable-...
L-type amino acid transporters (LAT) uptake neutral amino acids including L-leucine into cells, stimulating mTOR complex 1 (mTORC1) signaling and protein synthesis. LAT1 and LAT3 are overexpressed at different stages of prostate cancer and are involved in increasing nutrients and stimulating cell...
Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...
Short telomere length in peripheral blood mononuclear cells is associated with aging and such age-related diseases as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal...
In a recently reported phase III trial, denosumab (Xgeva) significantly increased bone metastasis–free survival and delayed time to first bone metastasis but did not improve overall survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer and baseline...
Some data support an association between circadian disruption and prostate cancer. In a study reported in Journal of the National Cancer Institute, Erin E. Flynn-Evans, PhD, of the Division of Sleep Medicine at Brigham and Women’s Hospital, and colleagues assessed the association between...
In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...
In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....
A number of initiatives have been implemented to encourage reduction of inappropriate use of imaging to stage incident prostate cancer. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by...
The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...
In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...
In a phase III double-blind study (VENICE trial) reported in Lancet Oncology, Ian F. Tannock, DSc, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the addition of the antiangiogenic agent aflibercept (Zaltrap) to standard docetaxel/prednisone therapy in patients with...